The PSL Alliance

We work closely with you to identify your needs and create strategies to help you achieve your financial ambitions.


About Axol Bioscience

Axol are world leaders in iPSC technology supporting the next generation of advanced models for drug discovery.

They provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, Axol support the pursuit of more human-relevant in vitro models to develop better, safer therapies.

They have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Their industry-leading iPSC capabilities support the pursuit of advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms. From simple monoculture models to complex co- and tri-culture and 3D models, Axol continue to pioneer the advanced utility of iPSCs for research and drug discovery.

hiPSCs, human disease and the Axol story

At Axol Bioscience, we support your pursuit of more effective, safer therapies.

Like you, we believe that having more human-relevant disease models which will expand your scientific knowledge and de-risk drug development. We use human iPSCs to achieve this and have been doing this since 2006.

We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models.

We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety.

When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patient selection.

With these data comes better insights, helping you de-risk projects, reduce costs and save time during drug development.


  • cells tissues